Jan T.M. van der Meer; Sven A. Danner
van der Meer J., Danner S.; Clarithromycin Therapy for Mycobacterium avium Complex Bacteremia. Ann Intern Med. 1995;123:154-155. doi: 10.7326/0003-4819-123-2-199507150-00015
Download citation file:
Published: Ann Intern Med. 1995;123(2):154-155.
TO THE EDITOR:
Chaisson and colleagues  found a good bacteremia-decreasing effect of all dosage schedules used. An early survival advantage was seen with the 500-mg twice-daily dose compared with higher doses. According to the authors, this difference was not a result of more severely ill patients being assigned to receive the higher doses. The authors also contend that the poor survival of patients receiving the 2000-mg twice-daily dose may have been related to the intolerance to clarithromycin of patients assigned to this dose. There was no difference in the number of dose-limiting reactions between patients assigned to the 500-mg and 1000-mg twice-daily dose, and the authors concluded that the survival advantage with the 500-mg twice-daily dose was not fully understood. They recommended use of the 500-mg twice-daily dose in the initial treatment of Mycobacterium avium complex bacteremia.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only